|
| Status |
Public on Jun 01, 2021 |
| Title |
KDM1B is an important regulator of cytokine signaling in the tumor immune microenvironment and response to immune checkpoint therapy (RNA-seq) |
| Organisms |
Homo sapiens; Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Tumor microenvironment (TME) plays an important role in immune evasion and resistance to immune checkpoint therapy. Here, by using genetic, epigenetic, tumor biology and immunology approaches, we unraveled a key function of KDM1B in TME. KDM1B is important for maintaining several pro-oncogenic cytokine/chemokine signaling pathways. In vivo in resistant and inflammatory breast cancer models, ablation of KDM1B in tumor cells results in increased T cell activity and significantly improved response to anti-PD-1/anti-CTLA-4 therapy. Thus, this study identifies KDM1B as a key regulator of tumor immune microenvironment and offered the mechanistical basis for using KDM1B inhibitors in combinatory therapy to overcome resistance to immune checkpoint blockade.
|
| |
|
| Overall design |
Use transcriptom analysis to examine the effect of KDM1B depletion to cancer cell in culture and tumors developed from s.q cancer cell injection.
|
| |
|
| Contributor(s) |
Fang R, Shi Y |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Aug 05, 2019 |
| Last update date |
Jun 01, 2021 |
| Contact name |
Yujiang Shi |
| E-mail(s) |
yujiang_shi@hms.harvard.edu
|
| Phone |
617-525-8097
|
| Organization name |
Brigham and Women's Hospital
|
| Department |
Division of Endocrinology, Diabetes and Hypertension
|
| Street address |
221 longwood Ave, EBRC (LMRC) 222A
|
| City |
Boston |
| State/province |
MA |
| ZIP/Postal code |
02115 |
| Country |
USA |
| |
|
| Platforms (2) |
|
| Samples (19)
|
|
| Relations |
| BioProject |
PRJNA558763 |
| SRA |
SRP217501 |
Less...
More...